低浓度阿托品治疗近视的临床研究进展  

Low-concentration atropine treatment for myopia

作　　者：孙远[1] 刘泉[1] 

机构地区：[1]中山大学中山眼科中心,广州510060

出　　处：《国际眼科纵览》2014年第4期241-244,共4页International Review of Ophthalmology

摘　　要：阿托品是毒蕈碱受体抑制剂,1％浓度滴眼可以抑制近视的发展及眼轴的增长,但是畏光、视近模糊等常见的副作用限制了其临床应用.近期研究者逐渐将兴趣转向低浓度阿托品（小于1％浓度）的临床研究,发现低浓度阿托品滴眼可以有效延缓近视发展,比1％浓度的阿托品副作用更小,疗效也更持久稳定.Atropine is the antagonist of muscarinic receptor.1％ atropine was found to be able to inhibit myopia progression long ago.However,its usage was restricted due to the frequently happened side effects,such as photophobia and near vision blur.Recently,the focus of researchers shifted to the low-concentration atropine,which was demonstrated to have effects of slowing the progression of myopia.Compared to 1％ atropine,the effect of low-concentration atropine is more sustained and durable,and the incidence of side effect is much more less.

关 键 词：近视/治疗 阿托品 屈光不正 毒蕈碱受体 

分 类 号：R778.11[医药卫生—眼科]